218 related articles for article (PubMed ID: 26427385)
1. Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis.
Corrêa MF; Fernandes JP
Curr Protein Pept Sci; 2016; 17(3):213-9. PubMed ID: 26427385
[TBL] [Abstract][Full Text] [Related]
2. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
[TBL] [Abstract][Full Text] [Related]
3. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
4. Metallochaperones Are Needed for Mycobacterium tuberculosis and Escherichia coli Nicotinamidase-Pyrazinamidase Activity.
Sheen P; Monsalve A; Campos J; Huerta R; Antiparra R; Arteaga H; Duran P; Bueno C; Kirwan DE; Gilman RH; Zimic M
J Bacteriol; 2020 Jan; 202(2):. PubMed ID: 31636108
[No Abstract] [Full Text] [Related]
5. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.
Raynaud C; Lanéelle MA; Senaratne RH; Draper P; Lanéelle G; Daffé M
Microbiology (Reading); 1999 Jun; 145 ( Pt 6)():1359-1367. PubMed ID: 10411262
[TBL] [Abstract][Full Text] [Related]
6. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Scorpio A; Nikaido H; Sun Z
J Bacteriol; 1999 Apr; 181(7):2044-9. PubMed ID: 10094680
[TBL] [Abstract][Full Text] [Related]
7. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
Stehr M; Elamin AA; Singh M
Expert Rev Anti Infect Ther; 2015 May; 13(5):593-603. PubMed ID: 25746054
[TBL] [Abstract][Full Text] [Related]
8. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
9. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide.
Sun Z; Zhang Y
Antimicrob Agents Chemother; 1999 Mar; 43(3):537-42. PubMed ID: 10049264
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis.
Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158
[TBL] [Abstract][Full Text] [Related]
11. Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
Rosen BC; Dillon NA; Peterson ND; Minato Y; Baughn AD
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855077
[TBL] [Abstract][Full Text] [Related]
12. In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
Gopal P; Tasneen R; Yee M; Lanoix JP; Sarathy J; Rasic G; Li L; Dartois V; Nuermberger E; Dick T
ACS Infect Dis; 2017 Jul; 3(7):492-501. PubMed ID: 28271875
[TBL] [Abstract][Full Text] [Related]
13. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
14. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.
Shi W; Zhang X; Jiang X; Yuan H; Lee JS; Barry CE; Wang H; Zhang W; Zhang Y
Science; 2011 Sep; 333(6049):1630-2. PubMed ID: 21835980
[TBL] [Abstract][Full Text] [Related]
15. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.
Salfinger M; Crowle AJ; Reller LB
J Infect Dis; 1990 Jul; 162(1):201-7. PubMed ID: 2113074
[TBL] [Abstract][Full Text] [Related]
16. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.
Speirs RJ; Welch JT; Cynamon MH
Antimicrob Agents Chemother; 1995 Jun; 39(6):1269-71. PubMed ID: 7574514
[TBL] [Abstract][Full Text] [Related]
17. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
[TBL] [Abstract][Full Text] [Related]
18. A novel inexpensive electrochemical sensor for pyrazinoic acid as a potential tool for the identification of pyrazinamide-resistant
Rueda D; Furukawa R; Fuentes P; Comina G; Rey De Castro NG; Requena D; Gilman RH; Sheen P; Zimic M
Int J Mycobacteriol; 2018; 7(3):275-281. PubMed ID: 30198510
[TBL] [Abstract][Full Text] [Related]
19. A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
Zimic M; Loli S; Gilman RH; Gutierrez A; Fuentes P; Cotrina M; Kirwan D; Sheen P
Microb Drug Resist; 2012 Aug; 18(4):372-5. PubMed ID: 22372927
[TBL] [Abstract][Full Text] [Related]
20. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants.
Jagadeb M; Rath SN; Sonawane A
J Cell Biochem; 2018 Sep; 119(9):7328-7338. PubMed ID: 29761826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
